Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.58 |
| ▸ | PI4KA | P42356 | 7/20 | 0.58 |
| ▸ | PI4K2B | Q8TCG2 | 7/20 | 0.58 |
| ▸ | PI4K2A | Q9BTU6 | 7/20 | 0.58 |
| ▸ | PI4KB | Q9UBF8 | 7/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.55 |
| ▸ | AHCY | P23526 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4298072 | 0.87 | ADORA2A (0.56) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL3922476 | 0.83 | ADORA2A (0.50) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL27818519 | 0.82 | ADORA2A (0.50) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL887808 | 0.81 | ADORA2A (0.59) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL27455290 | 0.80 | ADORA2A (0.49) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL29254213 | 0.80 | ADORA2A (0.48) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28327072 | 0.79 | CDK1 (0.59) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL9127128 | 0.78 | FAP (0.48) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL9683747 | 0.78 | ADORA2A (0.43) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL385843 | 0.77 | ADORA2A (0.55) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110172074-A | A kind of synthetic method of Aldoforwe ester | 湖北益泰药业股份有限公司 | 2019-08-27 | — | — | CN | claimed |
| CN-106699814-A | Preparation method of adefovir dipivoxil crystals | 辰欣药业股份有限公司 | 2017-05-24 | — | — | CN | claimed |
| EP-4689071-A2 | MRNA THERAPEUTICS FOR OOCYTE MATURATION | Eastern Virginia Medical School (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024206465-A2 | MRNA THERAPEUTICS FOR OOCYTE MATURATION | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2024-10-03 | — | — | WO | disclosed |
| WO-2023086465-A9 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | MODERNATX, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| EP-4359533-A2 | COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF GENES | Versameb AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| WO-2023220693-A1 | SYNTHETIC SELF-AMPLIFYING MRNA MOLECULES WITH SECRETION ANTIGEN AND IMMUNOMODULATOR | SunVax mRNA Therapeutics Inc. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4178585-A1 | LIPID NANOPARTICLES FOR DELIVERING THERAPEUTICS TO LUNGS | GENEVANT SCIENCES GMBH (CH) | 2023-05-17 | — | — | EP | disclosed |
| EP-4121018-A2 | CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS | GENEVANT SCIENCES GMBH (CH) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022269356-A2 | COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF GENES | VERSAMEB AG (CH) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022011156-A1 | LIPID NANOPARTICLES FOR DELIVERING THERAPEUTICS TO LUNGS | GENEVANT SCIENCES GMBH (US) | 2022-01-13 | — | — | WO | disclosed |
| CN-106317115-A | Preparation method of adefovir | 天津市亨必达化学合成物有限公司 | 2017-01-11 | — | — | CN | disclosed |
| CN-104530130-B | A kind of method preparing adefovir ester | 河南师范大学 | 2016-08-24 | — | — | CN | disclosed |
| CN-103012482-A | Process for synthesizing medicament for resisting hepatitis B virus | LI YAYUE | 2013-04-03 | — | — | CN | disclosed |
| CN-100361664-C | Pharmaceutical formulations | GILEAD SCIENCES INC (US) | 2008-01-16 | — | — | CN | disclosed |
| CN-101020693-A | Prepn process of Adefovir | UNIV ANHUI NORMAL (CN) | 2007-08-22 | — | — | CN | disclosed |
| CN-1682743-A | Pharmaceutical formulations | GILEAD SCIENCES INC (US) | 2005-10-19 | — | — | CN | disclosed |
| CN-1202829-C | Pharmaceutical formulations | GILEAD SCIENCES INC (US) | 2005-05-25 | — | — | CN | disclosed |
| CN-1347695-A | Nucleotide analogue composition | GILEAD SCIENCES INC (US) | 2002-05-08 | — | — | CN | disclosed |
| CN-1330547-A | Pharmaceutical formulations | GILEAD SCIENCES INC (US) | 2002-01-09 | — | — | CN | disclosed |